Under AAAResearchReports.com Microscope: Eli Lilly & Co., Bristol-Myers Squibb Co., Allergan Inc., and Endo Health Solutions Inc. PR Newswire LONDON, October 15, 2013 LONDON, October 15, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Monday, October 14, 2013, all three indexes of the US equity market ended higher. The Dow Jones Industrial Average ended the day at 15,301.26, up 0.42%; the S&P 500 closed at 1,710.14, up 0.41%; and the NASDAQ Composite finished at 3,815.28, up 0.62%. Shares of companies in the healthcare-drug makers sector ended on a mixed note, even as the broader market edged higher. The major movers included Eli Lilly and Company (NYSE: LLY), Bristol-Myers Squibb Company (NYSE: BMY), Allergan Inc. (NYSE: AGN), and Endo Health Solutions Inc. (NASDAQ: ENDP). AAAResearchReports.com has released full comprehensive research on LLY, BMY, AGN, and ENDP. These free technical analyses can be downloaded by signing up at: http://www.AAAResearchReports.com/register/ On Monday, Eli Lilly & Co.'s shares posted gains to end the day at $49.03, which is 0.31% higher than the previous day's closing price of $48.88. The company's shares fluctuated between $48.47 and $49.05 during the trading session. A total of 5.51 million shares were traded, which is above the daily average volume of 5.41 million. Eli Lilly & Co.'s shares have gained 2.23% in the previous three trading sessions, underperforming the S&P 500 which has advanced 3.24% during the same period. Further, the company's stock is trading above its 50-day and 200-day moving averages of $52.09 and $53.30, respectively. A free technical analysis on LLY available by signing up at: http://www.AAAResearchReports.com/LLY101513.pdf Shares in Bristol-Myers Squibb Co. fluctuated between gains and losses before finishing the day nearly flat on Monday. The company's shares ended the day at$47.67, down 0.02%, after fluctuating between$47.18 and$47.94 during the trading session. A total of 6.00 million shares were traded, which is below the daily average volume of 6.92 million. The company's shares have gained 4.06% in the last three months and 9.44% in the previous one month, compared to a gain of 1.78% and 1.31% in the S&P 500 during the respective periods. Furthermore, Bristol-Myers Squibb Co.'s stock is trading above its 50-day and 200-day moving averages of $44.23 and $41.55, respectively. Register today and access free research on BMY at: http://www.AAAResearchReports.com/BMY101513.pdf Allergan Inc.'s stock moved higher on Monday, extending the gains from the previous trading session. The company's shares ended the day 0.30% higher at $90.23 after oscillating between $89.29 and $90.37 during the trading session. A total of 1.97 million shares were traded, which is above the daily average volume of 1.88 million. The company's stock has gained 1.64% in the previous one month, compared to a gain of 1.31% in the S&P 500 during the same period. Additionally, Allergan Inc.'s stock is trading above its 50-day moving average of $89.97. The free report on AGN can be downloaded by signing up now at: http://www.AAAResearchReports.com/AGN101513.pdf Endo Health Solutions Inc.'s stock fell by 1.11% on Monday, even as the broader market finished on a positive note. The company's shares fluctuated between $44.13 and $44.83 before ending the day at $44.50. A total of 0.92 million shares were traded, which is below the daily average volume of 1.68 million. The company's shares have advanced 1.83% in the last one month and 13.46% in the previous three months, outperforming the S&P 500 which has gained 1.31% and 1.78% during the respective periods. Moreover, Endo Health Solutions Inc.'s stock is trading above its 50-day and 200-day moving averages of $41.97 and $35.58, respectively. A free report on ENDP can be accessed by registering at: http://www.AAAResearchReports.com/ENDP101513.pdf EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE AAA Research Reports Contact: Contact Name: Peter F. Jones - Phone #: +1(646)396-9126, Email ID: firstname.lastname@example.org
Under AAAResearchReports.com Microscope: Eli Lilly & Co., Bristol-Myers Squibb Co., Allergan Inc., and Endo Health Solutions
Press spacebar to pause and continue. Press esc to stop.